Tags

Type your tag names separated by a space and hit enter

Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Vaccine. 2019 12 10; 37(52):7547-7559.V

Abstract

BACKGROUND

To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV).

METHODS

Based on variability in disease burden, strength of health system and economic status, we selected four states in India: Bihar, New Delhi, Maharashtra and Tamil Nadu. We used secondary data sources to estimate the number of under-5 deaths averted from Hib, pneumococcus and rotavirus in each state and back-calculated the total cases averted. We synthesized available data to estimate the disease burden, treatment cost, caretaker productivity loss and vaccine coverage in each state. A Delphi Survey and roundtable among Indian experts was conducted to reach consensus on model inputs.

RESULTS

By scaling up coverage of Hib, PCV and RVV, India could save over US$1 billion (uncertainty range: US$0.9-US$2.4 billion) in economic benefits and avert more than 90,000 needless child deaths each year. An estimated US$1 billion (US$0.9-US$2 billion) or 88% of the total amount of cost savings would be attributable to lost productivity due to premature pneumococcal death. Another US$112.8 million (US$105-297 million), or 10% of the total cost would be accounted by costs related to loss of productivity due to disability as a result of these diseases. Treatment costs of Hib, pneumococcal disease and rotavirus gastroenteritis, would account for US$8.4 million (US$4-12 million) or <1% of the total costs of these diseases. Finally, caretaker productivity loss from seeking care would represent US$1.5 million (US$ 1-4.9 million). Cost savings varied by vaccine, coverage scenarios and states.

CONCLUSIONS

Hib, PCV and RVV vaccine introduction in India can result in immediate benefits to the government and households in terms of savings.

Authors+Show Affiliations

Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: dconste1@jhu.edu.China National Health Development Research Centre, Ministry of Health, Beijing, PR China; Peking University Health Science Center, No. 38 Xueyuan Rd., P.O. Box 218, Haidian District, Beijing 100191, PR China.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31607600

Citation

Constenla, D, and T Liu. "Estimating the Economic Impact of Pneumococcal Conjugate, Haemophilus Influenzae Type B and Rotavirus Vaccines in India: National and State-level Analyses." Vaccine, vol. 37, no. 52, 2019, pp. 7547-7559.
Constenla D, Liu T. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses. Vaccine. 2019;37(52):7547-7559.
Constenla, D., & Liu, T. (2019). Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses. Vaccine, 37(52), 7547-7559. https://doi.org/10.1016/j.vaccine.2019.09.084
Constenla D, Liu T. Estimating the Economic Impact of Pneumococcal Conjugate, Haemophilus Influenzae Type B and Rotavirus Vaccines in India: National and State-level Analyses. Vaccine. 2019 12 10;37(52):7547-7559. PubMed PMID: 31607600.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses. AU - Constenla,D, AU - Liu,T, Y1 - 2019/10/10/ PY - 2019/10/15/pubmed PY - 2020/10/9/medline PY - 2019/10/15/entrez KW - Diarrhea KW - Economics KW - India KW - Meningitis KW - Pneumonia KW - Savings KW - Vaccination SP - 7547 EP - 7559 JF - Vaccine JO - Vaccine VL - 37 IS - 52 N2 - BACKGROUND: To support vaccine decision-making we estimated from the societal perspective the potential health impact and costs averted through immunization with three vaccines - Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV) and rotavirus vaccine (RVV). METHODS: Based on variability in disease burden, strength of health system and economic status, we selected four states in India: Bihar, New Delhi, Maharashtra and Tamil Nadu. We used secondary data sources to estimate the number of under-5 deaths averted from Hib, pneumococcus and rotavirus in each state and back-calculated the total cases averted. We synthesized available data to estimate the disease burden, treatment cost, caretaker productivity loss and vaccine coverage in each state. A Delphi Survey and roundtable among Indian experts was conducted to reach consensus on model inputs. RESULTS: By scaling up coverage of Hib, PCV and RVV, India could save over US$1 billion (uncertainty range: US$0.9-US$2.4 billion) in economic benefits and avert more than 90,000 needless child deaths each year. An estimated US$1 billion (US$0.9-US$2 billion) or 88% of the total amount of cost savings would be attributable to lost productivity due to premature pneumococcal death. Another US$112.8 million (US$105-297 million), or 10% of the total cost would be accounted by costs related to loss of productivity due to disability as a result of these diseases. Treatment costs of Hib, pneumococcal disease and rotavirus gastroenteritis, would account for US$8.4 million (US$4-12 million) or <1% of the total costs of these diseases. Finally, caretaker productivity loss from seeking care would represent US$1.5 million (US$ 1-4.9 million). Cost savings varied by vaccine, coverage scenarios and states. CONCLUSIONS: Hib, PCV and RVV vaccine introduction in India can result in immediate benefits to the government and households in terms of savings. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/31607600/Estimating_the_economic_impact_of_pneumococcal_conjugate_Haemophilus_influenzae_type_b_and_rotavirus_vaccines_in_India:_National_and_state_level_analyses_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(19)31326-X DB - PRIME DP - Unbound Medicine ER -